“Kissei Pharmaceutical Co., Ltd. – Product Pipeline Review – 2015
Summary
Global Markets Direct’s, ‘Kissei Pharmaceutical Co., Ltd. – Product Pipeline Review – 2015’, provides an overview of the Kissei Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Kissei Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides brief overview of Kissei Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
– The report reviews current pipeline of Kissei Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
– The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
– Special feature on out-licensed and partnered product portfolio
– The report summarizes all the dormant and discontinued pipeline projects
– Latest company statement
– Latest news and deals relating to the Kissei Pharmaceutical Co., Ltd.’s pipeline products
Reasons to buy
– Evaluate Kissei Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
– Assess the growth potential of Kissei Pharmaceutical Co., Ltd. in its therapy areas of focus
– Identify new drug targets and therapeutic classes in the Kissei Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
– Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
– Develop strategic initiatives by understanding the focus areas of Kissei Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kissei Pharmaceutical Co., Ltd.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Explore the dormant and discontinued projects of Kissei Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
– Avoid Intellectual Property Rights related issues”
“Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Kissei Pharmaceutical Co., Ltd. Snapshot 6
Kissei Pharmaceutical Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Kissei Pharmaceutical Co., Ltd. – Research and Development Overview 7
Key Therapeutic Areas 7
Kissei Pharmaceutical Co., Ltd. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Pipeline Products – Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Kissei Pharmaceutical Co., Ltd. – Pipeline Products Glance 15
Kissei Pharmaceutical Co., Ltd. – Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Kissei Pharmaceutical Co., Ltd. – Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Kissei Pharmaceutical Co., Ltd. – Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Kissei Pharmaceutical Co., Ltd. – Drug Profiles 21
mitiglinide 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ozagrel 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
rovatirelin 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(remogliflozin etabonate + metformin hydrochloride) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
bedoradrine sulfate 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
KLH-2109 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
KWA-0711 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
remogliflozin etabonate 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
YS-110 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AS-192426900 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AS-192781900 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AS-193280400 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
KDT-3594 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KGO-2142 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
KGO-2173 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
KOM-1962 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
KTA-439 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
KTA-574 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Kissei Pharmaceutical Co., Ltd. – Pipeline Analysis 44
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Target 44
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration 46
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type 47
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action 48
Kissei Pharmaceutical Co., Ltd. – Recent Pipeline Updates 49
Kissei Pharmaceutical Co., Ltd. – Dormant Projects 53
Kissei Pharmaceutical Co., Ltd. – Discontinued Pipeline Products 54
Discontinued Pipeline Product Profiles 54
diquafosol tetrasodium 54
KGA-3235 54
KLS-0611 54
KUX-1151 54
remogliflozin etabonate 55
Kissei Pharmaceutical Co., Ltd. – Company Statement 56
Kissei Pharmaceutical Co., Ltd. – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60″
“List of Tables
Kissei Pharmaceutical Co., Ltd., Key Information 6
Kissei Pharmaceutical Co., Ltd., Key Facts 6
Kissei Pharmaceutical Co., Ltd. – Pipeline by Indication, 2015 8
Kissei Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2015 10
Kissei Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2015 11
Kissei Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2015 12
Kissei Pharmaceutical Co., Ltd. – Partnered Products in Pipeline, 2015 13
Kissei Pharmaceutical Co., Ltd. – Partnered Products/ Combination Treatment Modalities, 2015 14
Kissei Pharmaceutical Co., Ltd. – Pre-Registration, 2015 15
Kissei Pharmaceutical Co., Ltd. – Phase III, 2015 16
Kissei Pharmaceutical Co., Ltd. – Phase II, 2015 17
Kissei Pharmaceutical Co., Ltd. – Phase I, 2015 18
Kissei Pharmaceutical Co., Ltd. – Preclinical, 2015 19
Kissei Pharmaceutical Co., Ltd. – Discovery, 2015 20
Kissei Pharmaceutical Co., Ltd. – Pipeline by Target, 2015 44
Kissei Pharmaceutical Co., Ltd. – Pipeline by Route of Administration, 2015 46
Kissei Pharmaceutical Co., Ltd. – Pipeline by Molecule Type, 2015 47
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Mechanism of Action, 2015 48
Kissei Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2015 49
Kissei Pharmaceutical Co., Ltd. – Dormant Developmental Projects,2015 53
Kissei Pharmaceutical Co., Ltd. – Discontinued Pipeline Products, 2015 54
Kissei Pharmaceutical Co., Ltd., Other Locations 57
Kissei Pharmaceutical Co., Ltd., Subsidiaries 58″
“List of Figures
Kissei Pharmaceutical Co., Ltd. – Pipeline by Top 10 Indication, 2015 8
Kissei Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2015 10
Kissei Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2015 11
Kissei Pharmaceutical Co., Ltd. – Partnered Products in Pipeline, 2015 13
Kissei Pharmaceutical Co., Ltd. – Pipeline by Top 10 Target, 2015 44
Kissei Pharmaceutical Co., Ltd. – Pipeline by Top 10 Route of Administration, 2015 46
Kissei Pharmaceutical Co., Ltd. – Pipeline by Top 10 Molecule Type, 2015 47
Kissei Pharmaceutical Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2015 48″
